Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Recommendation of "Buy" from Brokerages

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) has earned an average recommendation of "Buy" from the ten brokerages that are presently covering the stock, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $40.38.

Several equities research analysts have issued reports on ORKA shares. Wedbush restated an "outperform" rating and set a $40.00 target price on shares of Oruka Therapeutics in a research report on Thursday, May 15th. BTIG Research started coverage on Oruka Therapeutics in a research note on Thursday, May 22nd. They issued a "buy" rating on the stock. HC Wainwright reaffirmed a "buy" rating and set a $45.00 price objective on shares of Oruka Therapeutics in a research note on Friday, February 7th. Wall Street Zen upgraded shares of Oruka Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Finally, Wolfe Research started coverage on shares of Oruka Therapeutics in a report on Tuesday, February 4th. They set an "outperform" rating and a $20.00 target price for the company.

Institutional Trading of Oruka Therapeutics

A number of hedge funds have recently bought and sold shares of ORKA. JPMorgan Chase & Co. bought a new position in Oruka Therapeutics in the 4th quarter worth $54,000. AlphaCentric Advisors LLC purchased a new stake in Oruka Therapeutics in the 4th quarter worth $119,000. China Universal Asset Management Co. Ltd. purchased a new stake in Oruka Therapeutics in the 4th quarter worth $144,000. AlphaQuest LLC purchased a new stake in Oruka Therapeutics in the 1st quarter worth $168,000. Finally, Cannon Global Investment Management LLC purchased a new stake in Oruka Therapeutics in the 1st quarter worth $195,000. Hedge funds and other institutional investors own 56.44% of the company's stock.

Oruka Therapeutics Stock Up 4.5%

Oruka Therapeutics stock traded up $0.49 during trading on Monday, hitting $11.44. The stock had a trading volume of 189,645 shares, compared to its average volume of 225,717. Oruka Therapeutics has a 1 year low of $5.49 and a 1 year high of $31.13. The stock's 50 day moving average is $9.78 and its two-hundred day moving average is $14.01. The stock has a market cap of $428.33 million, a price-to-earnings ratio of -1.83 and a beta of 0.25.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.17. As a group, equities research analysts anticipate that Oruka Therapeutics will post -3.41 EPS for the current fiscal year.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.